Physician profile
Albert Ing
NPI 1730144494
$8,323.92
in general payments reported to CMS, 2019-2025
30 companies · $785 in 2025
The $785 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $796 · 2021: $1,231 · 2022: $1,816 · 2023: $1,700 · 2024: $1,020 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,465 · Education: $39.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,464.87 |
| Education | $39.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,592.25 | 2019-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $1,219.23 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,088.25 | 2019-2024 | Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $866.43 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $714.09 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $485.31 | 2021-2024 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $360.66 | 2023-2024 | Inpefa |
| Pfizer INC. | $265.49 | 2019-2024 | |
| Abbott Laboratories | $256.12 | 2020-2024 | Gallant, Mitraclip |
| Irhythm Technologies, INC. | $197.82 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Biotronik INC. | $169.09 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $153.16 | 2020-2023 | Camzyos |
| Baxter Healthcare | $151.79 | 2025 | Hillrom - Cardiac Ambulatory Monitor, Perclot |
| Amgen INC. | $135.97 | 2023-2024 | Amjevita, Repatha |
| Astellas Pharma US INC | $117.82 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $109.83 | 2021-2024 | |
| Alnylam Pharmaceuticals INC. | $61.00 | 2021-2025 | Amvuttra |
| Esperion Therapeutics, INC. | $54.80 | 2024-2025 | Nexletol |
| Aurinia Pharma U.S., INC. | $46.54 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $36.97 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $35.99 | 2021-2023 | Arcalyst |
| Novo Nordisk INC | $28.14 | 2025 | Wegovy |
| Lantheus Medical Imaging, INC. | $27.79 | 2024 | |
| Boston Scientific Corporation | $27.36 | 2022 | |
| Philips North America LLC | $27.33 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.26 | 2023 | Entyvio |
| Abiomed | $22.50 | 2023 | Impella |
| Inspire Medical Systems, INC. | $17.94 | 2025 | Inspire |
| Amarin Pharma, INC. | $16.79 | 2022 | |
| Gilead Sciences, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Ing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.